Scientists address treatment duration and sequence considerations and discuss current targeted treatment dilemmas of chronic lymphocytic leukemia, where they review B cell lymphoma 2 inhibitors and Bruton’s tyrosine kinase in a fixed duration and continuous treatment manner.
[Hematological Oncology]
7992332
{7992332:BBBBBBBB}
apa
50
1
168490
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
